Ensysce Biosciences (ENSC) Other Accumulated Expenses (2020 - 2025)
Ensysce Biosciences (ENSC) posted quarterly Other Accumulated Expenses of $993411.0 for Q4 2025, up 81.13% year-over-year from $548458.0 in Q4 2024, and down 31.66% quarter-over-quarter from $1.5 million in Q3 2025.
Ensysce Biosciences (ENSC) Other Accumulated Expenses (2020 - 2025) Analysis & Trends
Ensysce Biosciences (ENSC) has reported Other Accumulated Expenses for 6 consecutive years, with $993411.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Other Accumulated Expenses rose 81.13% year-over-year to $993411.0; the TTM figure through Dec 2025 stood at $993411.0 (up 81.13% YoY), while the FY2025 annual figure was $993411.0, up 81.13% from the prior year.
- Other Accumulated Expenses fell to $993411.0 in Q4 2025 per ENSC's latest filing, from $1.5 million in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $3.7 million in Q3 2021 and bottomed at $370186.0 in Q2 2024.
- Historically, Other Accumulated Expenses has averaged $1.4 million across 5 years, with a median of $993411.0 in 2025.
- Annual changes were most pronounced in 2021 — Other Accumulated Expenses surged 888.29% — and 2024, when it slumped 82.68%.
- Ensysce Biosciences' Other Accumulated Expenses stood at $3.4 million in 2021, then tumbled by 34.66% to $2.2 million in 2022, then slumped by 75.65% to $542260.0 in 2023, then gained by 1.14% to $548458.0 in 2024, then jumped by 81.13% to $993411.0 in 2025.
- Business Quant data shows ENSC's Other Accumulated Expenses at $993411.0 in Q4 2025, $1.5 million in Q3 2025, and $1.0 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Ensysce Biosciences | 942,649.19 | -3.37 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 993,411.00 |
| Sep 30, 2025 | 1.45 Mn |
| Jun 30, 2025 | 1.05 Mn |
| Mar 31, 2025 | 888,498.00 |
| Dec 31, 2024 | 548,458.00 |
| Sep 30, 2024 | 447,035.00 |
| Jun 30, 2024 | 370,186.00 |
| Mar 31, 2024 | 408,435.00 |
| Dec 31, 2023 | 542,260.00 |
| Sep 30, 2023 | 760,458.00 |
| Jun 30, 2023 | 785,827.00 |
| Mar 31, 2023 | 2.36 Mn |
| Dec 31, 2022 | 2.23 Mn |
| Sep 30, 2022 | 2.24 Mn |
| Jun 30, 2022 | 2.67 Mn |
| Mar 31, 2022 | 1.75 Mn |
| Dec 31, 2021 | 3.41 Mn |
| Sep 30, 2021 | 3.73 Mn |
| Jun 30, 2021 | 411,941.00 |
| Dec 31, 2020 | 344,792.00 |